SCHEMBL4613245

SCHEMBL4613245

O=S(=O)(Cl)c1ccccc1S

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.44
HSD17B10 Q99714 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
TRPV4 Q9HBA0 4/20 0.39
GAA P10253 1/20 0.36
CA1 P00915 4/20 0.34
CA2 P00918 4/20 0.34
CA6 P23280 3/20 0.34
CA9 Q16790 3/20 0.34
CA4 P22748 2/20 0.34
MAPT P10636 2/20 0.34
CA12 O43570 2/20 0.34
CYP2C9 P11712 2/20 0.34
CA5A P35218 2/20 0.34
CA7 P43166 2/20 0.34
CA5B Q9Y2D0 2/20 0.34
CA14 Q9ULX7 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27875230 0.98 ALDH1A1 (0.42) ALDH1A1HSD17B10TDP1TRPV4GAA
SCHEMBL18421177 0.98 ALDH1A1 (0.42) ALDH1A1HSD17B10TDP1TRPV4GAA
SCHEMBL250199 0.81 ALDH1A1 (0.55) ALDH1A1HSD17B10TDP1TRPV4GAA
SCHEMBL30948577 0.79 GAA (0.50) ALDH1A1GAACA1CA2CA6
SCHEMBL3279998 0.79 GAA (0.50) ALDH1A1GAACA1CA2CA6
SCHEMBL29644921 0.75 BCAT2 (0.40) ALDH1A1GAACA1CA2CA6
SCHEMBL1048970 0.75 TSHR (0.44) ALDH1A1TDP1GAACA1CA2
SCHEMBL1806991 0.75 CA2 (0.56) GAACA1CA2CA6CA9
SCHEMBL944099 0.75 BCAT2 (0.40) ALDH1A1GAACA1CA2CA6
SCHEMBL10415459 0.74 GAA (0.50) ALDH1A1HSD17B10TDP1TRPV4GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111234803-A Ligand exchange method of quantum dots and quantum dot compound TCL集团股份有限公司 2020-06-05 CN claimed
CN-111234803-A Ligand exchange method of quantum dots and quantum dot compound TCL集团股份有限公司 2020-06-05 CN disclosed
CN-105381573-B Golf 邓禄普体育用品株式会社 2018-03-09 CN disclosed
EP-2668975-B1 Golf ball DUNLOP SPORTS CO LTD (JP) 2017-07-19 EP disclosed
CN-103446720-B Golf ball 邓禄普体育用品株式会社 2017-05-10 CN disclosed
EP-2669328-B1 Golf ball DUNLOP SPORTS CO LTD (JP) 2017-03-22 EP disclosed
EP-2668977-B1 Golf ball DUNLOP SPORTS CO LTD (JP) 2017-02-01 EP disclosed
CN-103446725-B Golf 邓禄普体育用品株式会社 2016-08-10 CN disclosed
CN-103418115-B Golf DUNLOP SPORTS CO., LTD. (JP) 2016-05-11 CN disclosed
CN-103418116-B Golf DUNLOP SPORTS CO., LTD. (JP) 2016-05-04 CN disclosed
CN-103372285-A Golf ball DUNLOP SPORTS CO LTD 2013-10-30 CN disclosed
CN-102526997-A Golf ball SRI SPORTS LTD 2012-07-04 CN disclosed
CN-102526995-A Golf ball SRI SPORTS LTD 2012-07-04 CN disclosed
CN-102485294-A Golf ball SRI SPORTS LTD 2012-06-06 CN disclosed
EP-1599477-B1 SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS HOFFMANN LA ROCHE (CH) 2008-01-30 EP disclosed
US-7148229-B2 Sulfonamide substituted xanthine derivatives HOFFMAN-LA ROCHE INC. (US) 2006-12-12 US disclosed
EP-1599477-A1 SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-11-30 EP disclosed
US-20040192708-A1 Sulfonamide substituted xanthine derivatives DUNTEN PETER W (US) 2004-09-30 US disclosed
WO-2004074288-A1 SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2004-09-02 WO disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192708-A1 Sulfonamide substituted xanthine derivatives GYS2, SLC5A1, SLC5A2 ALDH1A1 277/4885HSD17B10 293/4885TDP1 2475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.